Literature DB >> 10217314

Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique.

N Kohri1, Y Yamayoshi, H Xin, K Iseki, N Sato, S Todo, K Miyazaki.   

Abstract

We have investigated the oral bioavailability of granules of albendazole, a drug used for treating echinococcosis in man, prepared by the solid dispersion technique. Rapid dissolution and supersaturation were observed when hydroxypropylmethylcellulose and hydroxypropylmethylcellulose phthalate were used as carriers in the solid dispersion. They inhibited the crystallization of albendazole from the supersaturated solution and maintained an amorphous state for 8 h. Gastric acidity-controlled rabbits were used to evaluate the variation in absorption after oral administration of the albendazole solid dispersion. For rabbits with low gastric acidity the bioavailability of orally administered albendazole in the granular form prepared by solid dispersion was more than three times that of albendazole in physical mixtures. These results suggest that the bioavailability of albendazole in solid dispersions might be high even if there is a great variation in the gastric pH of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217314     DOI: 10.1211/0022357991772277

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  16 in total

1.  In vivo evaluation of modified gum karaya as a carrier for improving the oral bioavailability of a poorly water-soluble drug, nimodipine.

Authors:  Gedela V Murali Mohan Babu; Namballa R Kumar; Kasina H Sankar; Battu J Ram; Namburu K Kumar; Kolapalli V R Murthy
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

2.  Influence of Hydroxypropyl Methylcellulose on Metronidazole Crystallinity in Spray-Congealed Polyethylene Glycol Microparticles and Its Impact with Various Additives on Metronidazole Release.

Authors:  Ching Mien Oh; Paul Wan Sia Heng; Lai Wah Chan
Journal:  AAPS PharmSciTech       Date:  2015-05-02       Impact factor: 3.246

3.  Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Stuart Mudge; David Hayes; Richard N Upton
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

4.  Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption.

Authors:  Dave A Miller; James C DiNunzio; Wei Yang; James W McGinity; Robert O Williams
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique.

Authors:  A Mesnukul; K Yodkhum; J Mahadlek; T Phaechamud
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

6.  Solid Dispersion Matrix Tablet Comprising Indomethacin-PEG-HPMC Fabricated with Fusion and Mold Technique.

Authors:  A Mesnukul; K Yodkhum; T Phaechamud
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

7.  Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations.

Authors:  Laura Ceballos; Celina Elissondo; Laura Moreno; Marcela Dopchiz; Sergio Sánchez Bruni; Guillermo Denegri; Luis Alvarez; Carlos Lanusse
Journal:  Parasitol Res       Date:  2008-05-10       Impact factor: 2.289

8.  Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers.

Authors:  I M Rigter; H G Schipper; R P Koopmans; H J M van Kan; H W Frijlink; P A Kager; H-J Guchelaar
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

9.  Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation.

Authors:  Mengmeng Lu; Dan Xiong; Weiwei Sun; Tong Yu; Zixia Hu; Jiafeng Ding; Yunpeng Cai; Shizhuang Yang; Baoliang Pan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.

Authors:  Zhi-Jie Hou; Xi Luo; Wei Zhang; Fei Peng; Bai Cui; Si-Jin Wu; Fei-Meng Zheng; Jie Xu; Ling-Zhi Xu; Zi-Jie Long; Xue-Ting Wang; Guo-Hui Li; Xian-Yao Wan; Yong-Liang Yang; Quentin Liu
Journal:  Oncotarget       Date:  2015-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.